

## NOTICE OF CHANGE IN CORPORATE STRUCTURE

Pursuant to Section 4.9 of National Instrument 51-102  
Continuous Disclosure Obligations

### Item 1 Names of the Parties to the Transaction

BriaCell Therapeutics Corp. ("**Company**" or "**BriaCell**") BriaPro Therapeutics Corp. ("**BriaPro**" or "**SpinCo**").

### Item 2 Description of the Transaction

On August 31, 2023, BriaCell and BriaPro completed the previously announced plan of arrangement (the "**Arrangement**") pursuant to the arrangement agreement entered into between BriaCell and BriaPro dated May 24, 2023. Under the terms of the Arrangement, for each BriaCell common share held immediately prior to August 31, 2023, BriaCell shareholders received one (1) common share of SpinCo, and one (1) new common share of BriaCell (retiring their old common share) having the same terms and characteristics as the existing BriaCell common shares.

The Company's securities will remain listed on the NASDAQ Stock Market and Toronto Stock Exchange under the ticker symbols "BCTX", "BCTXW" and "BCT". The new BriaCell common shares began trading on September 5, 2023, under the symbol "BCT".

The CUSIP and ISIN numbers for the new BriaCell common shares are 107930109 and CA1079301091, respectively. The CUSIP and ISIN numbers for BriaPro are 107931107 and CA1079311074, respectively. There has been no change to the BriaCell share purchase warrants CUSIP or ISIN.

As a result of the Arrangement, BriaPro became an unlisted reporting issuer in the provinces of British Columbia, Ontario and Alberta.

### Item 3 Effective Date of the Transaction

August 31, 2023.

### Item 4 Name of Each Party, if any, that ceased to be a Reporting Issuer after the Transaction and of each Continuing Entity

Not applicable.

### Item 5 Date of the Reporting Issuer's First financial Year-End after the Transaction, if applicable

BriaPro's first financial year-end following the Effective Date will be July 31, 2024.

### Item 6 The Period, including comparative period, if any, of the Interim and Annual Financial Statements Required to be Filed for the Reporting Issuer's First Financial Year after the Transaction, if applicable

BriaPro will be required to file carve-out unaudited interim statements for the period ended October 31, 2023, no later than 60 days following such date and carve-out audited financial statements for the year ended July 31, 2024 no later than 120 days following such date.

**Item 7 Documents filed under NI 51-102 that describe the Transaction**

The terms of the Arrangement are summarized in:

- (a) BriaCell's proxy statement dated July 24, 2023; and
- (b) BriaCell's news releases dated May 25, 2023, August 18, 2023, August 25, 2023 and August 31, 2023,

copies of which have been filed on SEDAR and are available under BriaCell's profile at [www.sedar.com](http://www.sedar.com).

DATED: September 11, 2023.